Literature DB >> 1293054

Resistance of recent Neisseria gonorrhoeae isolates in Nigeria and outcome of single-dose treatment with ciprofloxacin.

J A Otubu1, G E Imade, A S Sagay, O A Towobola.   

Abstract

One hundred four patients (71 males, 33 females) with acute gonococcal urethritis or cervicitis were treated with a single oral 250 mg dose of ciprofloxacin at Jos University Teaching Hospital, Jos, Nigeria. All gonococcal strains were isolated from appropriate pre-treatment swabs. Penicillinase-producing Neisseria gonorrhoeae (PPNG) accounted for 72.8% of all isolates. In vitro sensitivity of gonococcal isolates to ciprofloxacin was 100%, while that to penicillin, ampicillin and co-trimoxazole was below 15%. Of the 104 patients treated with ciprofloxacin, 73 (70%) attended a follow-up visit. Seventy-three (100%) patients showed clinical cure and elimination of N. gonorrhoeae from the respective site of infection. Post-gonococcal urethritis or cervicitis believed to be due to concomitant chlamydial infection was found in 22 (30.1%) patients--18 males and four females. No adverse reactions were reported by any patient. Our findings show that a single oral dose of ciprofloxacin (250 mg) is well tolerated and effective in the treatment of uncomplicated gonorrhoea and is particularly useful in regions with a high prevalence of PPNG.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1293054     DOI: 10.1007/bf01710680

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  16 in total

1.  Infertility in Central Africa: infection is the cause.

Authors:  M Collet; J Reniers; E Frost; R Gass; F Yvert; A Leclerc; C Roth-Meyer; B Ivanoff; A Meheus
Journal:  Int J Gynaecol Obstet       Date:  1988-06       Impact factor: 3.561

2.  Penicillinase-producing Neisseria gonorrhoeae--United States, Florida.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1986-01-10       Impact factor: 17.586

3.  Gonorrhea, Trichomonas and Candida among gravid and nongravid women in cameroon.

Authors:  B T Nasah; R Nguematcha; M Eyong; S Godwin
Journal:  Int J Gynaecol Obstet       Date:  1980 Jul-Aug       Impact factor: 3.561

Review 4.  Overview of clinical experience with ciprofloxacin.

Authors:  A P Ball
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

5.  Rapid carbohydrate utilization test for the identification of Neisseria gonorrhoeae.

Authors:  H Young; I C Paterson; D R McDonald
Journal:  Br J Vener Dis       Date:  1976-06

6.  Treatment of penicillin-resistant Neisseria gonorrhoeae with oral norfloxacin.

Authors:  S R Crider; S D Colby; L K Miller; W O Harrison; S B Kerbs; S W Berg
Journal:  N Engl J Med       Date:  1984-07-19       Impact factor: 91.245

7.  Single dose ciprofloxacin for treating gonococcal infections in men.

Authors:  P S Loo; G L Ridgway; J D Oriel
Journal:  Genitourin Med       Date:  1985-10

8.  Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.

Authors:  W Cullmann; M Stieglitz; B Baars; W Opferkuch
Journal:  Chemotherapy       Date:  1985       Impact factor: 2.544

9.  Gonorrhea and female infertility in rural Uganda.

Authors:  O P Arya; S R Taber; H Nsanze
Journal:  Am J Obstet Gynecol       Date:  1980-12-01       Impact factor: 8.661

10.  Sexually transmitted diseases in tropical Africa. A review of the present situation.

Authors:  A O Osoba
Journal:  Br J Vener Dis       Date:  1981-04
View more
  2 in total

Review 1.  Antibiotic treatment of gonorrhoea--clinical evidence for choice.

Authors:  C Bignell
Journal:  Genitourin Med       Date:  1996-10

2.  Activities of three investigational fluoroquinolones (BAY y 3118, DU-6859a, and clinafloxacin) against Neisseria gonorrhoeae isolates with diminished susceptibilities to ciprofloxacin and ofloxacin.

Authors:  C J Carlyn; L J Doyle; C C Knapp; M D Ludwig; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.